Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from EQL Pharma AB ( (SE:EQL) ).
EQL Pharma AB reported a strong start to the financial year with a 30% increase in sales and a 34% rise in operating profit for the first quarter of 2025. The company received marketing approval for its key product Memprex in France and announced a new licensing deal in the BeNeLux region, signaling strategic growth in European markets. EQL is also focusing on expanding its product pipeline and market reach, aiming for a 30% sales growth for the full year and stabilizing its EBITDA margin at 25%.
More about EQL Pharma AB
EQL Pharma AB operates in the pharmaceutical industry, focusing on the development and sale of niche generic drugs. The company is expanding its market presence in Europe, particularly in Germany and the Netherlands, leveraging its experience in price-centric markets similar to the Nordics.
Average Trading Volume: 18,979
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.73B
For detailed information about EQL stock, go to TipRanks’ Stock Analysis page.